Scarica l'app Stockscreener
100.90
0.23%
0.23
Precedente Chiudi:
$100.67
Aprire:
$100.99
Volume 24 ore:
19.38M
Relative Volume:
4.73
Capitalizzazione di mercato:
$19.12B
Reddito:
$2.83B
Utile/perdita netta:
$-1.02B
Rapporto P/E:
-18.31
EPS:
-5.51
Flusso di cassa netto:
$194.14M
1 W Prestazione:
+50.53%
1M Prestazione:
+59.12%
6M Prestazione:
+77.36%
1 anno Prestazione:
+90.13%
Intervallo 1D:
$100.75
$101.04
Intervallo di 1 settimana:
$66.00
$101.87
Portata 52W:
$38.81
$101.87
Exact Sciences Corp Stock (EXAS) Company Profile
Nome
Exact Sciences Corp
Settore
Industria
Telefono
608-284-5700
Indirizzo
5505 ENDEAVOR LANE, MADISON, WI
Confronta EXAS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
100.90 | 19.07B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
587.48 | 215.18B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
227.39 | 156.94B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
725.91 | 55.05B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
151.25 | 41.12B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
224.90 | 36.97B | 15.90B | 1.28B | 2.21B | 7.2842 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-01-02 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-08-02 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2023-05-05 | Iniziato | UBS | Neutral |
| 2023-03-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-02-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2021-11-03 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Reiterato | BTIG Research | Buy |
| 2021-07-29 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-29 | Reiterato | Oppenheimer | Outperform |
| 2021-07-29 | Reiterato | Stifel | Buy |
| 2021-06-15 | Iniziato | Raymond James | Strong Buy |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Equal Weight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-29 | Downgrade | UBS | Buy → Neutral |
| 2020-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-04-02 | Iniziato | Evercore ISI | Outperform |
| 2020-01-10 | Ripresa | BTIG Research | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Dougherty & Company | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-17 | Reiterato | BofA/Merrill | Buy |
| 2019-10-01 | Ripresa | Craig Hallum | Buy |
| 2019-09-26 | Iniziato | Oppenheimer | Outperform |
| 2019-02-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-09-05 | Ripresa | The Benchmark Company | Hold |
| 2018-08-13 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-01-29 | Iniziato | Goldman | Neutral |
| 2018-01-08 | Reiterato | The Benchmark Company | Buy |
| 2017-11-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Downgrade | BTIG Research | Buy → Neutral |
Mostra tutto
Exact Sciences Corp Borsa (EXAS) Ultime notizie
Abbott’s (ABT) Exact Sciences Deal is “Very, Very Important,” Says Jim Cramer - Insider Monkey
Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover - MSN
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences CorporationEXAS - Barchart.com
Analysts Are Bullish on These Healthcare Stocks: Nano-X Imaging (NNOX), Exact Sciences (EXAS) - The Globe and Mail
Exact Sciences likely needs to see over $100/share in takeoveranalyst - MSN
Deal Dispatch: Abbott, TPG And Lonza Make Major Moves, M&M Custard And New Fortress Energy Struggle - Benzinga
Exact Sciences (EXAS): Wells Fargo Downgrades Rating, Raises Pri - GuruFocus
Abbott Laboratories to acquire Exact Sciences for $23B in largest-ever diagnostics deal - The Business Journals
Exact Sciences (EXAS) Receives Downgrade from William Blair | EX - GuruFocus
Abbott Labs stock to acquire Exact Sciences for $21 billion - Investing.com
Abbott Labs stock to acquire Exact Sciences for $21 billion By Investing.com - Investing.com UK
Exact Sciences (EXAS) Downgraded to Neutral by Guggenheim | EXAS Stock News - GuruFocus
EXAS: Barclays Downgrades Exact Sciences, Raises Price Target to $105 | EXAS Stock News - GuruFocus
Here Are Friday’s Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More - Yahoo Finance
Abbott Labs stock gains as UBS reiterates Buy rating on Exact Sciences deal - Investing.com
Abbott is buying Exact Sciences. Here’s why - Modern Healthcare News
Here Are Friday's Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More - 24/7 Wall St.
Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits - MSN
Exact Sciences joins Abbott, shares soar 18% on acquisition and growth prospects - Mugglehead Magazine
Abbott Eyes Exact Sciences: Market Stir - StocksToTrade
Halper Sadeh LLC Encourages CIVI, JAMF, EXAS Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Exact Sciences, Leader in Cancer Screening and Genomics Testing, to Join Abbott Laboratories in 2026 - Morningstar
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday - MSN
Abbott Laboratories $23B purchase of Cologuard maker Exact Sciences could have Arizona implications - The Business Journals
Abbott Laboratories to acquire Exact Sciences in deal worth up to $23B - The Business Journals
Why Exact Sciences Rallied Over 50% This Week - Nasdaq
Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here? - Yahoo Finance
Why Exact Sciences Stock Surged Today - Nasdaq
Abbott Laboratories, Exact Sciences make $23B deal with Bay Area implicationsSan Francisco Business Times - The Business Journals
EXAS Shares Soar Amid Acquisition Rumors - timothysykes.com
Exact Sciences (EXAS) Soars Over 17% in Stock Market Surge - GuruFocus
Watch Abbott to Buy Cancer-Screener Exact Sciences for $21 Billion - Bloomberg.com
Abbott buys Exact Sciences for $21B, marking major cancer diagnostics play - Medical Marketing and Media
Abbott bets on cancer screening with $23 billion Exact Sciences deal - Reuters
Abbott Laboratories to buy Exact Sciences in $23B deal - The Business Journals
Guggenheim Downgrades Exact Sciences (EXAS) to Neutral - StreetInsider
Abbott-Exact Sciences Deal Set to Shake Up Diagnostic Market with Cancer-Fighting Acquisition - inkl
What to know about Exact Sciences. The Madison company was sold to Abbottfor $23 billion. - Milwaukee Journal Sentinel
Abbott makes cancer screening play with $21B Exact Sciences buy - BioWorld MedTech
UBS maintains Exact Sciences stock rating at Neutral amid Abbott acquisition reports - Investing.com
Exact Sciences (EXAS) Shares Surge Nearly 18% - GuruFocus
PR News | Collected Strategies Works Exact Sciences’ DealThu., Nov. 20, 2025 - O'Dwyer's PR
Abbott Laboratories Makes $21 Billion Bet On Cancer Diagnostics - Finimize
Abbott to Buy Cologuard Maker Exact Sciences for $21 Billion - Bloomberg.com
Abbott to Acquire Exact Sciences for $21B - Medical Product Outsourcing
Abbott's $23 Billion Cancer Gambit: Snapping Up Exact Sciences to Revolutionize Diagnostics - WebProNews
Abbott Laboratories to buy Exact Sciences for $21B - Modern Healthcare News
Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics - Benzinga
Abbott to buy Cologuard maker Exact Sciences for $21 billion - Crain's Chicago Business
Exact Sciences stock jumps after Abbott confirms acquisition - Investing.com
Exact Sciences Corp Azioni (EXAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):